Kavanagh JE, Hearn AP, Dhariwal J, et al. - In this study, the real-world effectiveness of benralizumab was examined and any baseline characteristics associated with response to therapy were distinguished. Researchers evaluated outcomes in all severe eosinophilic asthma (SEA) patients commenced on benralizumab at our specialist centre. This analysis enrolled a total of 130 patients. The data exhibited that benralizumab led to significant improvements in all clinical outcome measures in a large real-world SEA cohort. The study found a lack of response in a minority and should be a focus for future evaluation.